Search company, investor...

Founded Year

2018

Stage

IPO | IPO

Total Raised

$317.23M

Date of IPO

2/23/2022

About Lepu Biotechnology

Lepu Biopharma (02157.HK) is a Chinese biopharmaceutical company focusing on tumor therapy.

Headquarters Location

2nd Floor, Building 41, No. 518, Xinzhuan Road, Songjiang District

Songjiang District, Shanghai, 201612,

China

+86-21-67696099

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Latest Lepu Biotechnology News

July 3 Financial Quick Takes: Mega-round for China’s Lepu; plus Citryll, Jibeier and Calliditas

Jul 3, 2019

July 3 Financial Quick Takes: Mega-round for China’s Lepu; plus Citryll, Jibeier and Calliditas 2:42 PM Share Shiyu Capital leads Lepu’s $131M A round  Lepu Biotechnology Co. Ltd. closed a RMB900 million ($130.7 million) series A round led by Shiyu Capital. Sumin Investment, Kaiyuan Guochuang, Suzhou Xinrui, Le Cheng Medical, and existing investor Lepu Medical Technology (Beijing) Co. Ltd. (SZSE:300003) participated in the financing. Founded last year, Lepu has PD-1 and PD-L1 inhibitors, an oncolytic virus and multiple antibody-drug conjugates (ADCs) in Phase I-III testing. Citryll raises €15M series A from Chinese and Dutch investors  Citryll B.V. (Oss, the Netherlands) raised €15 million ($16.9 million) in a series A round from ModiQuest B.V. (Oss, the Netherlands), BOM Brabant Ventures, the BrightGene International (Hong Kong) Ltd. unit of BrightGene Bio-medical technology Co. Ltd. (Suzhou, China) and Curie Capital. The company is developing antibodies that block the formation of neutrophil extracellular traps by binding to N-terminal citrullinated epitopes in histones, which could treat autoimmune diseases such as lupus and rheumatoid arthritis. Jibeier looks to list in Shanghai  The Shanghai Stock Exchange accepted an application from Jiangsu Jibeier Pharmaceutical Co. Ltd. (Zhenjiang, China) to list on its new science and technology innovation board. The company proposed to raise up to RMB690 million ($100.2 million). The pharma develops chemical preparations and traditional Chinese medicines. Calliditas raises $22.6M  A year after going public on NASDAQ Stockholm, renal disease company Calliditas Therapeutics AB (SSE:CALTX) raised SEK210.3 million ($22.6 million) through the sale of 3.5 million shares at SEK60 in a private placement. Investors included BVF Partners L.P. (see "Calliditas Raises Over $70M in Swedish IPO" ). User Sign in

Lepu Biotechnology Frequently Asked Questions (FAQ)

  • When was Lepu Biotechnology founded?

    Lepu Biotechnology was founded in 2018.

  • Where is Lepu Biotechnology's headquarters?

    Lepu Biotechnology's headquarters is located at 2nd Floor, Building 41, No. 518, Xinzhuan Road, Songjiang District, Songjiang District.

  • What is Lepu Biotechnology's latest funding round?

    Lepu Biotechnology's latest funding round is IPO.

  • How much did Lepu Biotechnology raise?

    Lepu Biotechnology raised a total of $317.23M.

  • Who are the investors of Lepu Biotechnology?

    Investors of Lepu Biotechnology include Vivo Capital, Shanghai Biomedical Industry Equity Investment Fund Management, Sunshine Riverhead Capital, Ping An Capital, Sunshine Insurance Group and 11 more.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.